Metoclo Hameln (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone, reducing the brain’s emetic response. It also antagonizes peripheral 5‑HT3 receptors and enhances acetylcholine release, which together stimulate gastrointestinal motility and accelerate gastric emptying.

The specific dose of Metoclo Hameln is determined by the prescribing clinician based on the indication, patient age, weight, renal function, and route of administration. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

Safety data for metoclopramide in pregnancy are limited, and the drug is generally classified as category B or C depending on the region. It should only be used if the potential benefit outweighs the risk. Breastfeeding mothers should consult a physician, as metoclopramide can be excreted in milk.

To place an order, submit an enquiry on the Metoclo Hameln product page at gnhindia.com, providing the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metoclopramide and ondansetron act on different receptors; metoclopramide blocks dopamine D2 and 5‑HT3 receptors while ondansetron selectively antagonizes 5‑HT3 receptors. Metoclopramide also promotes gastric motility, which ondansetron does not. Choice of therapy depends on the clinical scenario, patient tolerance, and physician preference.

Metoclo Hameln should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from light, moisture, and extreme temperature fluctuations to maintain stability.

Metoclo Hameln is supplied as a sterile injectable solution and can be given intravenously or intramuscularly by a qualified healthcare professional. The route, rate, and volume are determined by the prescriber based on the clinical indication and patient condition.

Serious adverse effects include extrapyramidal symptoms such as dystonia, tardive dyskinesia, neuroleptic malignant syndrome, severe allergic reactions, and elevated prolactin levels that may cause hormonal disturbances. Patients should be monitored for movement disorders, mood changes, and signs of hypersensitivity.

Metoclo Hameln is contraindicated in individuals with known hypersensitivity to metoclopramide or any component of the formulation, in patients with pheochromocytoma, and in those with a history of severe extrapyramidal reactions. Caution is advised for patients with Parkinson’s disease, seizure disorders, or severe renal impairment.